Monopar Therapeutics (NASDAQ: MNPR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.220 | -0.190 | 0.0300 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Monopar Therapeutics (NASDAQ: MNPR) through any online brokerage.
Other companies in Monopar Therapeutics’s space includes: Vincerx Pharma (NASDAQ:VINC), Cabaletta Bio (NASDAQ:CABA), Cellectar Biosciences (NASDAQ:CLRB), T2 Biosystems (NASDAQ:TTOO) and PhaseBio Pharmaceuticals (NASDAQ:PHAS).
The latest price target for Monopar Therapeutics (NASDAQ: MNPR) was reported by HC Wainwright & Co. on Monday, November 1, 2021. The analyst firm set a price target for 9.00 expecting MNPR to rise to within 12 months (a possible 347.76% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Monopar Therapeutics (NASDAQ: MNPR) is $2.01 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Monopar Therapeutics.
Monopar Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Monopar Therapeutics.
Monopar Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.